Amplitude Ventures
Amplitude Ventures is a leading venture capital firm focused on creating, building, and growing breakthrough healthcare companies. With a strong foundation in healthcare innovation, Amplitude Ventures aims to bring life-changing therapies to market, improving patient lives while delivering superior value to investors. The firm leverages its deep experience and strategic partnerships to support Canadian entrepreneurs in the healthcare sector, particularly in precision medicine, where they focus on enhancing diagnostics, developing targeted therapies, and integrating AI with biology.
Amplitude Ventures
Espace CDPQ, 3, Place Ville-Marie Suite 12350, Montreal, QC, H3B 0E7
What We Do
A biotech venture creation studio to discover, incubate, and drive innovation, enabling the launch of leading biotechnology companies. The fellowship brings together Canada's brightest health-focused PhD candidates, post docs, and MDs to explore biotech concepts and create novel health science companies.
Portfolio
Revolutionizing drug design using cryo-electron microscopy to add insights of protein visualization and molecule structure for safer and more effective therapies.
#Biotechnology
Focused on developing treatments for neurodegenerative and neurodevelopmental disorders. Lead program Pridopidine is in phase 3 trials for Huntington’s disease and ALS.
#Biotechnology
Developing a computational platform using machine learning for protein stabilization and identifying novel small molecules for rare diseases.
#Biotechnology
Leveraging single cell genomics to advance precision medicines against autoimmune diseases and cancer, using a large database of patient samples and machine learning.
#Biotechnology
Utilizing AI small molecule design platform with chemistry and biology expertise to design better drugs for various diseases.
#Biotechnology
Building a large database of structured drug and target information used globally by institutions, researchers, and companies.
#Biotechnology
Leader in developing cellular therapeutics from pluripotent stem cells, enabling large-quantity production of T-cells and other cells for cell therapy products.
#Biotechnology
Pioneering precision medicine approach to treat Long QT Syndrome via SGK1 inhibition, expanding to treat resistant and rare cancers.
#Biotechnology
Advancing a biologic therapy platform combining multi-specificity and multi-valency on a single molecule for transformative therapies.
#Biotechnology
Using AI platform to identify new disease targets and accelerate drug discovery and development for rare diseases.
#Biotechnology
Developing precision oncology drugs targeting tumour-specific vulnerabilities using CRISPR-enabled discovery platform. IPO on NASDAQ in June 2020.
#Biotechnology
Developing self-administered treatment for PSVT episodes. IPO on NASDAQ in May 2019.
#Biotechnology
Developed real-time MR-guidance and ultrasound platform for non-invasive ablative tools. IPO on TSX in June 2015.
#Biotechnology
Developing highly differentiated therapeutics using a suite of therapeutic platforms. IPO on NYSE in April 2017.
#Biotechnology